electroCore, Inc. Form 10-K Summary
Business context and reporting period
electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company developing and selling non-invasive vagus nerve stimulation technology. Its principal offerings are prescription gammaCore devices for headache conditions, Truvaga consumer wellness products, and TAC-STIM human-performance products. This Form 10-K covers the fiscal year ended December 31, 2023, with comparison to 2022; it is an annual filing rather than a quarterly report.
- VA/DoD was the largest customer channel, representing 60.1% of 2023 revenue.
- UK NHS sales under the MedTech Funding Mandate represented 7.5% of revenue.
- The Company had 68 full-time employees as of February 1, 2024.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net sales | $16.030 million | $8.592 million | +$7.438 million, or 87% |
| Gross profit | $13.226 million | $6.976 million | +$6.250 million |
| Gross margin | 83% | 81% | +2 percentage points |
| Operating loss | $(19.269) million | $(22.874) million | Improved by $3.605 million |
| Net loss | $(18.834) million | $(22.162) million | Improved by $3.328 million |
| Basic and diluted loss per share | $(3.42) | $(4.69) | Improved |
| Net cash used in operating activities | $(14.668) million | $(16.645) million | Use decreased by $1.977 million |
| Cash, cash equivalents and restricted cash | $10.581 million | $17.962 million | Down $7.381 million |
Revenue by channel was $9.636 million from VA/DoD gammaCore, $1.797 million from U.S. commercial gammaCore, $1.821 million from international sales, $1.027 million from Truvaga, and $1.749 million from TAC-STIM. Excluding inventory charges, gross margin was 86.8% in 2023 versus 83.5% in 2022.
Research and development expense declined to $5.321 million from $5.520 million, while selling, general and administrative expense increased to $27.174 million from $24.330 million. The 2023 SG&A increase included $464,000 of severance charges and higher variable selling and marketing costs.
The balance sheet showed total assets of $16.102 million, total liabilities of $8.660 million, and stockholders’ equity of $7.442 million at December 31, 2023. The filing identifies no material conventional long-term debt; liabilities principally consisted of accounts payable, accrued expenses, operating lease liabilities, and approximately $247,000 remaining under insurance-premium financing at year-end.
Material changes versus the prior comparable period
- Net sales increased 87%, led by VA/DoD gammaCore sales, TAC-STIM, and Truvaga. TAC-STIM revenue rose to $1.749 million from $125,000, and Truvaga revenue rose to $1.027 million from $15,000.
- Gross margin improved despite $0.7 million of inventory charges in 2023 compared with $0.2 million in 2022. Management cited longer-duration therapy sales, higher average selling prices, refill kits, and A2PEX-related revenue.
- Operating and net losses narrowed, but the Company remained unprofitable and generated substantial negative operating cash flow.
- In August 2023, the Company raised approximately $7.5 million net through a registered direct offering and concurrent private placements involving common stock, pre-funded warrants, and warrants. The financing increased shares outstanding and created potential future dilution.
- Cash and restricted cash declined by $7.381 million during 2023 despite the financing, reflecting continued operating cash use.
- The Company completed a 1-for-15 reverse stock split effective February 15, 2023; historical share and per-share amounts were retrospectively adjusted.
Guidance, outlook, risks and unusual items
Management expects continued investment in U.S. and UK sales and marketing, direct-to-consumer and cash-pay channels, and the next generation of its therapy-delivery platform. It plans to launch an app-enabled Truvaga product, referred to as Truvaga Plus, in 2024. Management expects research and development expense to decrease in 2024 but expects substantial negative operating cash flow to continue.
The auditor’s report and management’s disclosures raise substantial doubt about the Company’s ability to continue as a going concern within one year of issuance of the financial statements. Management believes current cash and anticipated revenue may fund planned operations for 12 months, but acknowledges significant uncertainty and the possible need to reduce activities, obtain additional financing, or potentially cease operations.
- The existing VA Federal Supply Schedule contract was extended through June 14, 2024, while the replacement application is reviewed. Failure to obtain a replacement could materially reduce government-channel sales.
- Revenue is highly concentrated: VA/DoD represented 60.1% of 2023 revenue, and eight VA/DoD facilities represented approximately 63.8% of VA/DoD-channel revenue.
- NICE is expected to review UK guidance in 2024; changes to recommendations or pricing could affect NHS revenue. The NHS catalogue listing has been extended through March 17, 2026, with an option for an additional two years.
- Third-party payor coverage and reimbursement for gammaCore remain limited and uncertain, increasing reliance on government contracts and cash-pay channels.
- The Company depends on third-party manufacturers and suppliers, including suppliers in China, and has paused deliveries from certain suppliers, creating potential supply-chain and reactivation risks.
- The Company faces significant regulatory, clinical, product liability, cybersecurity, privacy, intellectual property, competition, foreign exchange, and government-contracting risks.
- The Company reported a material weakness in internal control over financial reporting related to vendor-management and payment-security controls. The weakness did not result in an identified misstatement, but disclosure controls were ineffective as of December 31, 2023 and remediation remains ongoing.
- Pending securities litigation remains subject to appeal. The Company has not accrued a loss because it cannot estimate the probability or range of potential loss.
- Unusual 2023 items included $464,000 of severance expense, $0.7 million of inventory charges, and a $173,000 casualty loss net of insurance recovery. An additional $123,000 casualty recovery was expected to be recognized in the first quarter of 2024.
Most important facts for investors to verify
- Whether the VA replacement FSS contract is approved and whether government-channel sales remain stable after June 14, 2024.
- Actual cash burn, available liquidity, financing needs, and the timing and terms of any future capital raise.
- Progress toward profitability and positive operating cash flow despite continued losses.
- Adoption, margins, and customer-acquisition economics for Truvaga, TAC-STIM, direct-to-consumer, and cash-pay programs.
- The outcome of the NICE review and the sustainability of NHS funding and reimbursement arrangements.
- Remediation and subsequent testing of the material weakness in vendor-payment controls.
- Potential dilution from outstanding warrants, options, restricted stock units, and the remaining capacity under the $75 million shelf registration statement.
- Developments in the securities litigation appeal and any resulting defense costs, settlement, or judgment.